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ABSTRACT
Background and Objectives: 2018 ESC/ESH Hypertension guideline recommends 
2-drug combination as initial anti-hypertensive therapy. However, real-world evidence 
for effectiveness of recommended regimens remains limited. We aimed to compare the 
effectiveness of first-line anti-hypertensive treatment combining 2 out of the following 
classes: angiotensin-converting enzyme (ACE) inhibitors/angiotensin-receptor blocker (A), 
calcium channel blocker (C), and thiazide-type diuretics (D).
Methods: Treatment-naïve hypertensive adults without cardiovascular disease (CVD) who 
initiated dual anti-hypertensive medications were identified in 5 databases from US and 
Korea. The patients were matched for each comparison set by large-scale propensity score 
matching. Primary endpoint was all-cause mortality. Myocardial infarction, heart failure, 
stroke, and major adverse cardiac and cerebrovascular events as a composite outcome 
comprised the secondary measure.
Results: A total of 987,983 patients met the eligibility criteria. After matching, 222,686, 
32,344, and 38,513 patients were allocated to A+C vs. A+D, C+D vs. A+C, and C+D vs. A+D 
comparison, respectively. There was no significant difference in the mortality during total 
of 1,806,077 person-years: A+C vs. A+D (hazard ratio [HR], 1.08; 95% confidence interval 
[CI], 0.97−1.20; p=0.127), C+D vs. A+C (HR, 0.93; 95% CI, 0.87−1.01; p=0.067), and C+D vs. 
A+D (HR, 1.18; 95% CI, 0.95−1.47; p=0.104). A+C was associated with a slightly higher risk of 
heart failure (HR, 1.09; 95% CI, 1.01−1.18; p=0.040) and stroke (HR, 1.08; 95% CI, 1.01−1.17; 
p=0.040) than A+D.
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Conclusions: There was no significant difference in mortality among A+C, A+D, and C+D 
combination treatment in patients without previous CVD. This finding was consistent across 
multi-national heterogeneous cohorts in real-world practice.
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INTRODUCTION
High blood pressure (BP) is the leading global cause of death and disability.1) While extensive 
evidence supports the beneficial effects of rapid BP control below the target in preventing 
mortality and cardiovascular disease (CVD),2) initial treatment with monotherapy is often 
insufficient or slow to achieve the BP target.3) Observational studies and meta-analyses 
have suggested that initial combination of hypertensive treatments confers a decreased 
risk for CVD compared to monotherapy.4-6) Therefore 2018 European Society of Cardiology 
(ESC)/European Society of Hypertension (ESH) guideline recommends dual combination 
treatment as initial therapy in most hypertensive patients rather than monotherapy.7) Despite 
the evidences from previous randomized controlled trials (RCTs) that directly compared 
the effects of different combination regimens,8-11) the optimal first-line antihypertensive 
combination regimen is a matter of controversy because 1) the results were heterogeneous, 2) 
the baseline characteristics of the study population were mostly at a high risk for CVD, and 3) 
most participants had taken anti-hypertension medications at baseline in these RCTs.
Therefore, we aimed to compare the therapeutic effectiveness of dual combination regimens 
in large cohorts of treatment-naïve hypertensive patients without CVD at baseline who 
initiated treatment with 2 out of the following 3 classes of drugs: angiotensin system 
blockage (angiotensin converting enzyme inhibitors [ACEIs]/angiotensin-receptor blockers 
[ARBs]), calcium channel blockers (CCBs), and thiazide diuretics (TZDs).
METHODS
Data source
The study consisted of a retrospective analysis of five data sources encoded in the 
Observational Medical Outcome Partnership (OMOP) Common Data Model (CDM) version 
5 from participating research partners across the Observational Health Data Sciences and 
Informatics (OHDSI) community.12) All 5 data sources are administrative claims databases: 
OptumInsight's Clinformatics™ Data Mart (CEDM, 79,600,000 subjects), Truven MarketScan 
Commercial Claims and Encounters (CCAE, 135,000,000 subjects), Truven MarketScan 
Medicare Supplemental Beneficiaries (Medicare, 9,800,000 subjects), Truven MarketScan 
Multi-State Medicaid (Medicaid, 25,500,000 subjects) from US, and the National Health 
Insurance Service-National Sample Cohort (NHIS-NSC, 1,100,000 subjects)13) from Korea.
This study was performed through a network model of OHDSI, where access to data and 
statistical testing was executed inside each data partner's institution. The entire analytical 
process was pre-specified before execution. Only pre-specified aggregated results lacking 
patient-level information were collected for interpretation and meta-analysis. Each data 
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partner obtained the necessary Institutional Review Board (IRB) approval or exemption (IRB 
number: AJIRB-MED-EXP-17-054).
Study population
The cohort included adults (≥20 years) with hypertension whose first anti-hypertensive 
treatment was initiated with recommended first-line dual combination regimens from 2001 
to 2017. The entry date in the cohort (index date) was defined as the date of first prescription 
of one of the combination drugs. The second class of antihypertensive medications should 
have been started within 30 days after index date. Only patients, enrolled in the database 
for at least 1 year before the index date, were included to avoid left censoring. Patients who 
had a prescription containing an ACEI/ARB, β-blocker, CCB, or TZD during the 12 months 
preceding the index date were excluded to limit the study to treatment-naïve subjects. The 
list of anti-hypertensive drugs is presented in the Supplementary Table 1. Patients who had a 
previous history of ischemic heart disease, stroke, or heart failure before the index date were 
also excluded.
Exposure
Three matched cohorts using the recommended combination treatments were created: ACEI/
ARB+CCB (A+C) vs. ACEI/ARB+TZD (A+D), CCB+TZD (C+D) vs. A+C, and C+D vs. A+D. 
The exposure was started when one drug of interest was prescribed without history of any 
anti-hypertensive medication within previous 365 days. Continuous drug exposures were 
constructed by allowing fewer than 30-day gaps between prescriptions. Only patients who 
continued both classes of drugs for more than 180 days were included in the primary analysis. 
Patients starting a third class of drug within 180 days of the index date were excluded.
Outcomes
The primary outcome was all-cause mortality occurring at least 180 days after the index date. 
The secondary outcomes were incident myocardial infarction (MI) requiring hospitalization, 
stroke requiring hospitalization, heart failure requiring hospitalization, and major adverse 
cardiac and cerebrovascular events (MACCE) as a composite outcome including MI, stroke, 
heart failure, and mortality occurring at least 180 days after the index date. Diagnosis codes 
for outcomes are listed in Supplementary Table 2.
Statistical analysis
Large-scale propensity score (PS)14) matching was used to balance the differences in 
baseline characteristics between treatment groups (R, "CohortMethod” package). PS was 
estimated using L1-regularized large-scale logistic regression models based on all available 
demographic characteristics, medical, medication, and procedure history with the L1 
penalty hyper-parameter selected through 10-fold cross-validation using high-performance 
computing.15) The details of covariates for propensity score matching and prespecified 
statistical analysis plan are presented in supplemental statistical analytic plan.
The PS was transformed to preference scores that account for differences in drug prevalence 
and availability. Confounding control was assessed by preference score distributions and 
covariate balance metrics. One-to-one greedy-search matching was used to match patients 
using a caliper of 0.15 times the standard deviation of the propensity score distribution. Cox 
proportional hazards models were used to compare the matched cohorts. After combining 
the results from five data sources, random effects model meta-analysis was performed to 
calculate summary hazard ratios and rate differences.
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The same analytical process was adopted for subgroup and sensitivity analyses. Subgroup 
analyses included stratification by age (<60 years and ≥60 years) and gender. Medicare data 
were not included in the subgroup analysis for younger patients.
A pre-specified p<0.05 was considered statistically significant for all two-sided tests. The 
entire analytical protocol and code is available on github (https://github.com/OHDSI/
StudyProtocolSandbox/tree/master/HypertensionCombination) for reproducibility, which 
enables other researchers to perform and replicate this study with any database in the format 
of OMOP-CDM.
Sensitivity analyses
To assess the robustness of results with respect to the definition of combination treatment, 
we re-ran the same analyses using 30-day, 1-year, and 2-year periods of initial regimen 
continuation. This could also estimate proportion of continuation over 180 days and the 
trend of survival difference along the duration of the initial regimen continuation.16)
A total of 39 negative control outcomes were employed to quantify systematic error.17) 
These negative control outcomes were unlikely to have a relationship with anti-hypertensive 
medications, identified through a data-rich algorithm.18) For further calibration of p values for 
the outcomes, we fit an empirical null distribution to these negative control point estimates 
to allow further calibration of p values.19) While also pre-specified, sensitivity and subgroup 
analyses were nonetheless regarded exploratory. After collection of the results, the meta-analysis 
aggregating only the results from US data sources was conducted as a sensitivity analysis.
RESULTS
Baseline characteristics of study population
A total of 1,062,605 patients were identified across five data sources. Three one-to-one 
propensity-score-matched cohorts were created by comparing A+C vs. A+D (n=445,372), 
C+D vs. A+C (n=64,688), and C+D vs. A+D (n=77,026). Among these patients, the covariates 
were well-balanced between treatment regimens after PS matching in each data source. The 
aggregated baseline characteristics of the study population across data sources before and 
after PS matching of three comparisons are summarized in Table 1. The PS distribution and 
the baseline characteristics of each data source before and after matching are presented in 
Supplementary Figure 1 and Supplementary Tables 3-7.
The total follow-up duration was 1,806,077 person-years (mean, 3.1 years). The median age 
ranged from 55 to 59 years in A+C vs. A+D, 60 to 64 years in C+D vs. A+C, and 60 to 64 years 
in C+D vs. A+D comparison. Approximately one-third of study patients (29.6–35.6%) had 
been treated with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors 
previously. The frequency of patients with a history of diabetes ranged from 13.6% to 21.4% 
and was the highest in the A+C and A+D comparison. About one-fifth of the cohort from 
NHIS-NSC also had results from a national health examination during the previous year of 
enrollment. Most examination measurements including BP were balanced after matching 
other patient characteristics, even though data from examinations were not included in the 
model to calculate the propensity score (Supplementary Table 7).
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Primary and secondary outcome assessment
For the primary outcome of overall mortality, there were no significant differences between 
any of the combination treatment in each data source (Figure 1). Moreover, the summary 
hazard ratio (HR) from 5 data sources did not demonstrate a statistically significant 
difference in mortality between recommended dual combination regimens (summary rate 
difference [RD], 0.53 [95% confidence interval {CI}, −0.06 to 1.13] per 1,000 person-years; 
summary HR, 1.08 [95% CI, 0.97 to 1.20]; p=0.127 for A+C vs. A+D; summary RD, −0.45 
[95% CI, −0.95 to 0.04]; summary HR, 0.93 [95% CI, 0.87 to 1.01]; p=0.067 for C+D vs. 
A+C; summary RD, 0.72 [95% CI, −0.74 to 2.18]; summary HR, 1.18 [95% CI, 0.95 to 1.47]; 
p=0.104 for C+D vs. A+D) (Figure 2).
The result for secondary outcomes is summarized in Figure 3. The combination treatment 
regimens had similar effectiveness for prevention of MI (all p>0.05). A+C combination was 
associated with slightly higher risk of heart failure compared to A+D combination (summary 
HR, 1.09 [95% CI, 1.01 to 1.18]; p=0.040). A+C combination also was related with worse 
outcome for stroke admission compared to A+D combination (summary HR, 1.08 [95% CI, 
1.01 to 1.17]; p=0.040). MACCE risk was not different across the matched cohorts (summary 
HR, 1.05 [95% CI, 1.00 to 1.11]; p=0.051 for A+C vs. A+D; summary HR, 1.01 [95% CI, 0.85 
to 1.21]; p=0.857 for C+D vs. A+C; summary HR, 1.12 [95% CI, 0.85 to 1.43]; p=0.263 for C+D 
vs. A+D). The relationship between combination treatment and secondary outcome in each 
data source is described in Supplementary Figure 2.
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Table 1. Baseline characteristics of all propensity-score-matched patients
Characteristics
A+C vs. A+D C+D vs. A+C C+D vs. A+D
A+C  
(n=222,686)
A+D 
(n=222,686) SD (%)
C+D  
(n=32,344)
A+C  
(n=32,344) SD (%)
C+D  
(n=38,513)
A+D  
(n=38,513) SD (%)
Age group
≤40 11,797 (5.3) 11,980 (5.4) 0.4 1,639 (5.1) 1,623 (5.0) 0.2 1,903 (4.9) 1,939 (5.0) 0.4
40–49 37,084 (16.7) 36,837 (16.5) 0.3 4,794 (14.8) 4,812 (14.9) 0.2 5,567 (14.5) 5,427 (14.1) 0.1
50–59 73,936 (33.2) 73,964 (33.2) <0.1 9,525 (29.4) 9,580 (29.6) 0.4 11,217 (29.1) 11,164 (29.0) 0.3
60–69 58,696 (26.4) 58,327 (26.2) 0.4 8,429 (26.1) 8,266 (25.6) 1.2 10,074 (26.2) 10,089 (26.2) 0.1
70–79 28,323 (12.7) 28,538 (12.8) 0.3 5,222 (16.1) 5,349 (16.5) 1.1 6,486 (16.8) 6,640 (17.2) 1.1
≥80 12,763 (5.7) 12,966 (5.7) 0.4 2,695 (8.3) 2,685 (8.3) 0.1 3,236 (8.4) 3,231 (8.4) <0.1
Gender
Women 93,676 (42.1) 90,820 (40.8) 2.6 18,762 (58.0) 19,574 (60.5) 5.1 23,537 (61.1) 23,938 (62.2) 2.1
Comorbidities
Diabetes mellitus, type II 47,256 (21.2) 47,730 (21.4) 0.5 4,815 (14.9) 4,719 (14.6) 0.8 5,305 (13.8) 5,225 (13.6) 0.6
Chronic kidney disease 5,963 (2.7) 6,081 (2.7) 0.3 889 (2.7) 954 (2.9) 1.2 997 (2.6) 1,048 (2.7) 0.8
Atrial fibrillation 3,343 (1.5) 3,280 (1.5) 0.2 611 (1.9) 601 (1.9) 0.2 685 (1.8) 706 (1.8) 0.4
Valvular heart disease 6,671 (3.0) 6,818 (3.1) 0.4 959 (3.0) 953 (2.9) 0.1 1,098 (2.9) 1,100 (2.9) 0.0
Dyslipidemia 106,065 (47.6) 106,372 (47.8) 0.3 13,413 (41.5) 13,107 (40.5) 1.9 15,598 (40.5) 15,375 (39.9) 1.2
Malignant neoplastic disease 17,722 (8.0) 17,985 (8.1) 0.4 2,826 (8.7) 2,842 (8.8) 0.2 3,357 (8.7) 3,369 (8.7) 0.1
Medication
HMG-CoA reductase 
inhibitors
79,028 (35.5) 79,291 (35.6) 0.2 9,949 (30.8) 9,718 (30.0) 1.6 11,393 (29.6) 11,467 (29.8) 0.4
Hypoglycemic drugs except 
insulin
34,989 (15.7) 35,354 (15.9) 0.4 3,301 (10.2) 3,285 (10.2) 0.2 3,549 (9.2) 3,486 (9.1) 0.6
Insulin 4,726 (2.1) 4,747 (2.1) 0.1 462 (1.4) 421 (1.3) 1.1 463 (1.2) 452 (1.2) 0.3
Antithrombotic agent 10,789 (4.8) 10,902 (4.9) 0.2 2,221 (6.9) 2,210 (6.8) 0.1 2,808 (7.3) 2,846 (7.4) 0.4
Values are presented as number of patients (%) not otherwise specified.
A = angiotensin converting enzyme inhibitors/angiotensin-receptor blockers; C = calcium-channel blocker; D = thiazide diuretics; HMG-CoA = 3-hydroxy-3-
methylglutaryl coenzyme A; SD = standardized difference.
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Figure 1. Kaplan-Meier plots for overall survival comparing different dual combination treatments in propensity score-matched cohorts from each data source. 
(A) CEDM, (B) CCAE, (C) Medicare, (D) Medicaid, and (E) NHIS-NSC. 
A = angiotensin converting enzyme inhibitors/angiotensin-receptor blockers; C = calcium-channel blocker; CCAE = Truven MarketScan Commercial Claims and 
Encounters; CEDM = OptumInsight's Clinformatics™ Data Mart; D = thiazide diuretics; Medicaid = Truven MarketScan Multi-State Medicaid; Medicare = Truven 
MarketScan Medicare Supplemental Beneficiaries; NHIS-NSC = National Health Insurance Service-National Sample Cohort.
Subgroup analysis
The summary HRs of overall mortality in subgroups stratified by gender and age are depicted 
in Figure 4. In women, A+C therapy was related with worse survival than A+D therapy 
(summary HR, 1.20 [95% CI, 1.09 to 1.31]; p=0.006). In men, C+D therapy was associated 
with worse survival outcome compared to A+D therapy (summary HR, 1.31 [95% CI, 1.12 
to 1.53]; p=0.009). There was no difference in overall mortality between recommended 
combination therapies in young (<60 years) and old patient (≥60 years) groups.
Sensitivity analyses
The proportion of patients with adherence to initial combination therapy was about two-
thirds for 365 days and about one-thirds for 730 days compared to 180 days: 63.7% in A+C, 
61.7% in A+D, 62.2% in C+D group for 365 days; 31.6% in A+C, 29.5% in A+D, 28.6% in C+D 
group for 730 days. A+C cohorts with minimum 365 days on continuation of combination 
therapy showed worse survival than A+D cohorts (summary HR, 1.15 [95% CI, 1.03 to 1.29]; 
p=0.026). Other results from the sensitivity analyses using various minimum periods of 
dual drug continuation did not indicate any significant difference in all-cause mortality 
(Supplementary Figure 3).
In the absence of bias, estimates among 95% of negative control outcomes are theoretically 
expected to include a HR of 1. Among 39 negative control outcomes, less than 5% analyses 
had a significant relationship with the specific combination treatment. All results from 
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A
B
C
p=0.127
p=0.067
p=0.104
Figure 2. Forest plots depicting HR and 95% CI for primary outcome in each data source. The overall HRs were calculated using a random-effects model. The 
size of data markers indicates the weight of the study. Error bars indicate 95% CIs. (A) A+C vs. A+D, (B) C+D vs. A+C, and (C) C+D vs. A+D. 
A = angiotensin converting enzyme inhibitors/angiotensin-receptor blockers; C = calcium-channel blocker; CCAE = Truven MarketScan Commercial Claims and 
Encounters; CEDM = OptumInsight's Clinformatics™ Data Mart; CI = confidential interval; D = thiazide diuretics; HR = hazard ratio; Medicaid = Truven MarketScan 
Multi-State Medicaid; Medicare = Truven MarketScan Medicare Supplemental Beneficiaries; NHIS-NSC = National Health Insurance Service-National Sample Cohort. 
*Event rate per 1,000 person-year.
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Figure 3. Forest plots depicting HR and 95% CI for secondary outcomes in each data source. The overall HRs were calculated using a random-effects model. The 
size of data markers indicates the weight of the study. Error bars indicate 95% CIs. (A) Myocardial infarction, (B) Heart failure, (C) Stroke, and (D) MACCE. 
A = angiotensin converting enzyme inhibitors/angiotensin-receptor blockers; C = calcium-channel blocker; CCAE = Truven MarketScan Commercial Claims 
and Encounters; CEDM = OptumInsight's Clinformatics™ Data Mart; CI = confidential interval; D = thiazide diuretics; HR = hazard ratio; MACCE = major adverse 
cardiac and cerebrovascular event; Medicaid = Truven MarketScan Multi-State Medicaid; Medicare = Truven MarketScan Medicare Supplemental Beneficiaries; 
NHIS-NSC = National Health Insurance Service-National Sample Cohort. 
*Event rate per 1,000 person-year. (continued to the next page)
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Figure 3. (Continued) Forest plots depicting HR and 95% CI for secondary outcomes in each data source. The overall HRs were calculated using a random-
effects model. The size of data markers indicates the weight of the study. Error bars indicate 95% CIs. (A) Myocardial infarction, (B) Heart failure, (C) Stroke, and 
(D) MACCE. 
A = angiotensin converting enzyme inhibitors/angiotensin-receptor blockers; C = calcium-channel blocker; CCAE = Truven MarketScan Commercial Claims 
and Encounters; CEDM = OptumInsight's Clinformatics™ Data Mart; CI = confidential interval; D = thiazide diuretics; HR = hazard ratio; MACCE = major adverse 
cardiac and cerebrovascular event; Medicaid = Truven MarketScan Multi-State Medicaid; Medicare = Truven MarketScan Medicare Supplemental Beneficiaries; 
NHIS-NSC = National Health Insurance Service-National Sample Cohort. 
*Event rate per 1,000 person-year.
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Figure 4. Forest plots depicting HR and 95% CI for primary outcome in subgroups. The overall HRs were calculated using a random-effects model. The size of 
data markers indicates the weight of the study. Error bars indicate 95% CIs. (A) Women, (B) Men, (C) ≥60 years, (D) <60 years. 
A = angiotensin converting enzyme inhibitors/angiotensin-receptor blockers; C = calcium-channel blocker; CCAE = Truven MarketScan Commercial Claims 
and Encounters; CEDM = OptumInsight's Clinformatics™ Data Mart; CI = confidential interval; D = thiazide diuretics; HR = hazard ratio; MACCE = major adverse 
cardiac and cerebrovascular event; Medicaid = Truven MarketScan Multi-State Medicaid; Medicare = Truven MarketScan Medicare Supplemental Beneficiaries; 
NHIS-NSC = National Health Insurance Service-National Sample Cohort. 
*Event rate per 1,000 person-year. (continued to the next page)
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Figure 4. (Continued) Forest plots depicting HR and 95% CI for primary outcome in subgroups. The overall HRs were calculated using a random-effects model. 
The size of data markers indicates the weight of the study. Error bars indicate 95% CIs. (A) Women, (B) Men, (C) ≥60 years, (D) <60 years. 
A = angiotensin converting enzyme inhibitors/angiotensin-receptor blockers; C = calcium-channel blocker; CCAE = Truven MarketScan Commercial Claims 
and Encounters; CEDM = OptumInsight's Clinformatics™ Data Mart; CI = confidential interval; D = thiazide diuretics; HR = hazard ratio; MACCE = major adverse 
cardiac and cerebrovascular event; Medicaid = Truven MarketScan Multi-State Medicaid; Medicare = Truven MarketScan Medicare Supplemental Beneficiaries; 
NHIS-NSC = National Health Insurance Service-National Sample Cohort. 
*Event rate per 1,000 person-year.
analysis of negative control outcomes are presented in Supplementary Figure 4. Calibrated 
p values based on the results of negative control outcomes analysis are also shown in 
Supplementary Table 8. The finding from the meta-analysis combining only the results 
from the US data sources was concordant with the finding from meta-analysis combining 
all results including the results from NHIS-NSC. All confidential intervals of the HR were 
overlapped for primary and secondary outcomes (Supplementary Table 9).
DISCUSSION
Based on the results of this real-world retrospective cohort study, there appears to be no 
significant difference in all-cause mortality between A+C, A+D, and C+D combination as 
first-line treatments of hypertension. This finding is consistent across the heterogeneous 
cohorts in both US and Korea, regardless of variability in the healthcare system. There was a 
slight benefit with initial A+D combination treatment for heart failure and stroke prevention 
over A+C.
To the best of our knowledge, this is the first study comparing effectiveness of first-line dual 
anti-hypertensive combinations in patients without CVD at baseline. Dual combination 
treatment in hypertension increases effectiveness and reduces adverse effects compared to 
monotherapy.5)20) 2018 ESC/ESH guideline recommends anti-hypertensive therapy should be 
initiated with combination regimen preferentially based on A+C or A+D.7) Notwithstanding, 
the evidence for head-to-head comparison of the combination regimens has been scarce.
In 2008, Jamerson et al. reported benefits of A+C treatment over A+D in reducing 
cardiovascular events in Western patients with high risk for CVD.8) Conversely, two 
Japanese studies did not demonstrate a significant difference between various combination 
regimens in preventing cardiovascular events. Matsuzaki et al.21) compared the CCB-based 
combinations with ARB, β-blocker, or TZD and demonstrated that all three combinations 
had similar efficacy for prevention of CVD and the achievement of target BP in population 
without high risk for CVD. Moreover, in a study by Ogihara et al.,9) there was no significant 
difference in terms of reduction of cardiovascular events between a combination of ARB and 
CCB versus ARB and TZD. In a meta-analysis analyzing the aforementioned RCTs, the all-
cause mortality was not different between A+C and other combinations.22)
It is well-known that TZD is better for the prevention of heart failure compared to CCB.23)24) 
Although a previous meta-analysis demonstrated that CCB is the most effective drug class 
for stroke prevention, the protective effects of CCB for stroke were not significant compared 
to TZD.23)24) In this study, A+D treatment was associated with lower incidence of heart failure 
and stroke compared to A+C treatment, which should be interpreted with caution. A+D also 
showed benefits over A+C in women. A previous study reported that CCB monotherapy was 
associated with a greater risk of cardiovascular death compared to diuretics monotherapy in 
women.25) However, in another meta-analysis, there was no significant gender difference in 
efficacy among various classes of anti-hypertensive agents between men and women.26) The 
long-term effectiveness of dual anti-hypertensive combinations between sexes should be 
investigated further.
For assessing study robustness and residual systemic error, extensive efforts were made, 
including analysis of negative control outcomes. We demonstrated that body mass index, 
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systolic BP, smoking history, and other laboratory measures were well-matched in the sub-
cohort of NHIS-NSC after PS matching even though these variants were not included in the 
PS model. Furthermore, the results from analyses on various minimum drug continuation 
periods were consistent. The numbers of patients who took the initial combination therapy 
for at least 365 days and 730 days were about two-thirds and one-third of the number in the 
original 180-day cohort, respectively. Although this number is low, it is in line with a previous 
cohort study in Italy, which demonstrated a medication discontinuation rate of 41% at 1 year 
and 50% at 5 years after initiation of monotherapy.27)
Consistent findings demonstrated across the US and Asian cohorts analyzed under the same 
pre-specified analysis suggest generalizability of the study. Since all protocols and analytic 
codes are available publicly, the detailed review and reproduction of this study is possible. 
Still, this study carries several limitations. First, because of the nature of retrospective 
study, the true balance of baseline characteristics between cohorts and accuracy of non-
fatal cardiovascular outcomes cannot be guaranteed. Although this problem can only be 
solved by RCTs, a randomized outcomes study to compare three different regimens in 
treatment-naïve hypertensive patients without previous CVD is unlikely to be feasible. 
Second, we could not assess the racial proportions in data sources except in the Medicaid, 
although we demonstrated that there was no difference in the effectiveness of combination 
regimens between US and Korean populations. Third, the overall mortality rate might be 
underestimated in the four US administrative datasets, because only hospital-reported 
mortality was captured in these data sources. Fourth, we did not adjust for dosage of anti-
hypertensive medications and single-pill combinations. Although adherence to the single-pill 
combination is reported to be higher than individual-pill combination, the meta-analysis 
concluded that beneficial effects of single-pill combination in changes to BP or adverse 
effects was not significant.28) To assess potential bias caused by compliance, we replicated 
the same analysis in the cohorts with various initial regimen continuation periods, in which 
the results were consistent with those of the primary analysis. Fifth, although a recent meta-
analysis showed no significant differences in cardiovascular outcomes between ACEIs and 
ARBs,29) whether these two classes of drugs can be considered a single class may be a matter 
of controversy. Lastly, an aggregate meta-analysis approach without pooling the individual 
data can be another limitation of this study. Nonetheless, a previous study demonstrated that 
an aggregate meta-analysis approach generates estimates at least as accurate and precise as 
pooled dataset analysis, especially when the effects of interest are heterogeneous.30)
In conclusion, this is the first observational study comparing effectiveness of first-line dual 
combination treatments in multi-national heterogeneous cohorts in real-world practice. 
In this study, there is no significant difference in mortality among recommended dual 
combination treatment regimens in treatment-naïve hypertensive patients without previous 
CVD. This finding provides evidence for comparable effectiveness between recommended 
initial anti-hypertensive combination treatments in real-world practice.
ACKNOWLEDGEMENTS
The analysis is based in part on work from the Observational Health Sciences and 
Informatics (OHDSI) collaborative. OHDSI is a multi-stakeholder, interdisciplinary 
collaborative to create open-source solutions that reveal the value of observational health 
data through large-scale analytics.
64https://e-kcj.org https://doi.org/10.4070/kcj.2019.0173
Combination Therapy in Hypertension
SUPPLEMENTARY MATERIALS
Supplementary Table 1
Drug code list
Click here to view
Supplementary Table 2
Disease code list
Click here to view
Supplementary Table 3
Baseline characteristics in CEDM before and after propensity score matching
Click here to view
Supplementary Table 4
Baseline characteristics in CCAE before and after propensity score matching
Click here to view
Supplementary Table 5
Baseline characteristics in Medicare before and after propensity score matching
Click here to view
Supplementary Table 6
Baseline characteristics in Medicaid before and after propensity score matching
Click here to view
Supplementary Table 7
Baseline characteristics in NHIS-NSC before and after propensity score matching
Click here to view
Supplementary Table 8
Calibrated p-values in each data source
Click here to view
Supplementary Table 9
Meta-analysis using the result from the four US data sources
Click here to view
65https://e-kcj.org https://doi.org/10.4070/kcj.2019.0173
Combination Therapy in Hypertension
Supplementary Figure 1
PSs distribution before and after matching. (A), CEDM, (B) CCAE, (C) Medicare, (D) Medicaid, 
and (E) NHIS-NSC.
Click here to view
Supplementary Figure 2
Kaplan-Meier plots for secondary outcomes comparing different dual combination treatment in 
propensity score-matched cohorts from each data source. (A) Myocardial infarction, (B) Stroke, 
(C) Heart failure, and (D) MACCE.
Click here to view
Supplementary Figure 3
All-cause mortality in patients with various drug periods.
Click here to view
Supplementary Figure 4
Funnel plot of negative control outcomes in each data source. (A) CEDM, (B) CCAE, (C) Medicare, 
(D) Medicaid, and (E) NHIS-NSC. A total of 39 negative control outcomes are shown as blue dots 
and the primary outcome (overall mortality) as yellow diamonds. The area below the dash line 
indicated estimates with p<0.05. The orange area indicates estimates with calibrated p<0.05. 
Overall, less than 5% of negative controls showed significant association with the treatment.
Click here to view
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